Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis
of brain impairment caused by chronic hyperglycemia is complex and includes …

Alzheimer's disease (AD), characterized by the aggregation of amyloid-β (Aβ) protein and
neuroinflammation, is the most common neurodegenerative disease globally. Previous …

Abstract Glucagon-like peptide-1 (GLP-1) is a 30 amino acid long peptide hormone derived
from the proglucagon gene and secreted in the distal small intestine when food enters the …

Like type‐2 diabetes mellitus (T2DM), neurodegenerative disorders and stroke are an ever
increasing, health, social and economic burden for developed Westernized countries. Age is …

ABSTRACT Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however,
its function in the brain is not well studied. In this systematic review, we aimed to analyze the …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Glucagon-like peptide-1 (GLP-1) is released in response to meals and exerts important roles
in the maintenance of normal glucose homeostasis. GLP-1 is also important in the regulation …

Recent clinical guidelines have emphasized the importance of screening for cognitive
impairment in older adults with diabetes, however, there is still a lack of understanding about …

The current understanding of neurodegenerative processes in sporadic diseases such as
Alzheimer's disease (AD), Parkinson's disease (PD) or multiple sclerosis is very limited …

The public and social health burdens of ischemic stroke have been increasing worldwide.
Hyperglycemia leads to a greater risk of stroke. This increased risk is commonly seen …